Su1352 Clinical Impact of a Discard Strategy Based on FICE and Magnifying Colonoscopy for the In Vivo Histology Prediction of Small Colorectal Polyps

2012 ◽  
Vol 75 (4) ◽  
pp. AB303
Author(s):  
Claudio R. Teixeira ◽  
Lix a. Oliveira ◽  
Luciana F. Figueiredo ◽  
Mauro Maia ◽  
Cibele Canali ◽  
...  
2017 ◽  
Vol 112 ◽  
pp. S53
Author(s):  
Kirtipal Bhatia ◽  
Bijun S. Kannadath ◽  
Paaras Kohli ◽  
Julie Guider ◽  
Nancy Behazin ◽  
...  

2018 ◽  
Vol 23 (11) ◽  
pp. 1 ◽  
Author(s):  
Yubo Tang ◽  
Alexandros D. Polydorides ◽  
Sharmila Anandasabapathy ◽  
Rebecca R. Richards-Kortum

Author(s):  
Irene Isabel López-Torres ◽  
Javier Vaquero-Martín ◽  
Ana-Isabel Torres-Suárez ◽  
Federico Navarro-García ◽  
Ana-Isabel Fraguas-Sánchez ◽  
...  

Abstract Purpose Microencapsulation techniques have allowed the addition of rifampicin to bone cement, but its in vivo efficacy has not been proven. The aim of our study is to determine the superiority of cement containing gentamicin and rifampicin microcapsules in the treatment of PJI versus cement exclusively containing gentamicin. Methods An S. aureus PJI was induced in 15 NZW rabbits. A week after inoculation, the first stage of replacement was carried out, and the animals were divided into two groups: group R received a spacer containing gentamicin and rifampicin microcapsules, and group C received a spacer containing gentamicin. Intra-articular release curve of rifampicin and infection and toxicity markers were monitored for four weeks post-operatively, when microbiological analysis was performed. Results The microbiological cultures showed a significantly lower growth of S. aureus in soft tissue (2.3·104 vs 0; p = 0.01) and bone (5.7·102 vs 0; p = 0.03) in the group with rifampicin microcapsules. No differences were found in systemic toxicity markers. Rifampicin release from the cement spacer showed higher concentrations than the staphylococcal MIC throughout the analysis. Conclusion The in vivo analyses demonstrated the superiority of cement containing gentamicin and rifampicin microcapsules versus the isolated use of gentamicin in the treatment of PJI in the rabbit model without serious side effects due to the systemic absorption of rifampicin. Given the increasing incidence of staphylococci-related PJI, the development of new strategies for intra-articular administration of rifampicin for its treatment has a high clinical impact.


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S329-S329
Author(s):  
Lawrence Friedrich ◽  
Marla Curran ◽  
Surya Chitra ◽  
Amy Manley ◽  
Stephen Bai ◽  
...  

Abstract Background Omadacycline (OMC) is an intravenous (IV) and oral aminomethylcycline antibiotic in the tetracycline class approved in the United States to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adults. The approved dosing regimens of OMC include a loading dose designed to achieve steady-state exposures early in the course of therapy. We assessed the impact on OMC exposure and subsequent pharmacodynamics (PD) on Day 2 and at steady state (Day 5) in the situation where a loading dose may not be given. Methods Phase 1 pharmacokinetic (PK) data were used to determine OMC exposure on Day 2 and at steady state (Day 5) for the following: IV regimens 100 mg IV q12h on Day 1 then 100 mg IV QD (load), 100 mg IV QD (no load); and oral regimens 450 mg oral QD on Days 1 and 2 then 300 mg QD (load) and 300 mg oral QD (no load). AUCs on Day 2 and Day 5 for no-load regimens were compared with the regimens with loading doses. Additionally, AUC:MIC ratios were calculated using OMC MIC90 for two main pathogens of interest in ABSSSI and CABP, respectively, Staphylococcus aureus (0.25 mg/L) and Streptococcus pneumoniae (0.12 mg/L). In vivo AUC:MIC targets for stasis and 1-log kill used were 21.9 and 57.7 (S. aureus) and 31.2 and 65.8 (S. pneumoniae). Results Day 2 and 5 AUCs are shown in the Figure. AUCs on Day 2 were lower for the two regimens without loading doses and were 72% (IV) and 73% (oral) of those with a loading dose. However, at steady state on Day 5, no-load regimen AUCs were essentially the same at 98% for both the IV and oral regimens. Despite lower AUCs on Day 2 for the no-load regimens, the AUC:MIC ratio would still be expected to exceed the stasis threshold for both pathogens and the 1-log kill threshold for S. pneumoniae (figure). This same pattern was also noted on Day 5. Conclusion Exposure as assessed using AUC was lower early on in therapy on Day 2 for both IV and oral regimens. However, exposures were not different on Day 5 at steady state. Despite lower exposure on Day 2, OMC would still be expected to meet or exceed PK/PD thresholds associated with stasis for S. aureus and S. pneumoniae. The 1-log kill threshold was exceeded for S. pneumoniae. Further studies are needed to confirm any clinical impact of the omission of OMC loading doses. Disclosures All authors: No reported disclosures.


2020 ◽  
Vol 13 ◽  
pp. 175628482091065 ◽  
Author(s):  
Tsuyoshi Ozawa ◽  
Soichiro Ishihara ◽  
Mitsuhiro Fujishiro ◽  
Youichi Kumagai ◽  
Satoki Shichijo ◽  
...  

Background: Recently the American Society for Gastrointestinal Endoscopy addressed the ‘resect and discard’ strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in object recognition. Therefore, we aimed to construct an AI system that can accurately detect and classify CP using stored still images during colonoscopy. Methods: We used a deep convolutional neural network (CNN) architecture called Single Shot MultiBox Detector. We trained the CNN using 16,418 images from 4752 CPs and 4013 images of normal colorectums, and subsequently validated the performance of the trained CNN in 7077 colonoscopy images, including 1172 CP images from 309 various types of CP. Diagnostic speed and yields for the detection and classification of CP were evaluated as a measure of performance of the trained CNN. Results: The processing time of the CNN was 20 ms per frame. The trained CNN detected 1246 CP with a sensitivity of 92% and a positive predictive value (PPV) of 86%. The sensitivity and PPV were 90% and 83%, respectively, for the white light images, and 97% and 98% for the narrow band images. Among the correctly detected polyps, 83% of the CP were accurately classified through images. Furthermore, 97% of adenomas were precisely identified under the white light imaging. Conclusions: Our CNN showed promise in being able to detect and classify CP through endoscopic images, highlighting its high potential for future application as an AI-based CP diagnosis support system for colonoscopy.


2016 ◽  
Vol 83 (5) ◽  
pp. AB454-AB455
Author(s):  
Kazuki Kato ◽  
Shin-ei Kudo ◽  
Atsushi Katagiri ◽  
Kunihiko Wakamura ◽  
Takemasa Hayashi ◽  
...  

2018 ◽  
Vol 12 (1) ◽  
pp. 1-12
Author(s):  
Bini Mathew ◽  
Judith V. Hobrath ◽  
Michele C. Connelly ◽  
R. Kiplin Guy ◽  
Robert C. Reynolds

Background:Sulindac belongs to the chemically diverse family of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that effectively prevent adenomatous colorectal polyps and colon cancer, especially in patients with familial adenomatous polyposis. Sulindac sulfide amide (SSA), an amide analog of sulindac sulfide, shows insignificant COX-related activity and toxicity while enhancing anticancer activityin vitroand demonstratingin vivoxenograft activity.Objective:Develop structure-activity relationships in the sulindac amine series and identify analogs with promising anticancer activities.Method:A series of sulindac amine analogs were designed and synthesized and then further modified in a “libraries from libraries” approach to produce amide, sulfonamide and N,N-disubstituted sulindac amine sub-libraries. All analogs were screened against three cancer cell lines (prostate, colon and breast).Results:Several active compounds were identifiedviain vitrocancer cell line screening with the most potent compound (26) in the nanomolar range.Conclusion:Compound26and analogs showing the most potent inhibitory activity may be considered for further design and optimization efforts as anticancer hit scaffolds.


Sign in / Sign up

Export Citation Format

Share Document